Age (y) | 68 ± 9† |
Men | 26 (76) |
Body mass index (kg/m2) | 25 ± 4 |
Risk factors | |
Smoking (ex or current) | 8 (24) |
Diabetes | 2 (6) |
Hypertension | 10 (29) |
Hypercholesterolemia | 2 (6) |
Antitumor therapy | |
Radiotherapy | 10 (29) |
Immunochemotherapy | 21 (62) |
Medication at baseline | |
Zoledronic acid (Zometa; Novartis) | 19 (56) |
Denosumab (Xgeva; Amgen) | 9 (26) |
Serum biochemistry† | |
Cholesterol at baseline (mg/dL) | 198 ± 58 |
Cholesterol at follow-up (mg/dL) | 199 ± 59 |
C-reactive protein at baseline (mg/dL) | 0.7 ± 0.7 |
C-reactive protein at follow-up (mg/dL) | 0.7 ± 0.6 |